Press coverage about Cytosorbents (NASDAQ:CTSO) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cytosorbents earned a news impact score of 0.23 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 46.6693389801485 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Cytosorbents Corporation (NasdaqCM:CTSO), Och-Ziff Capital Management Group LLC (NYSE:OZM) Showing … (concordiareview.com)
- Cytosorbents (CTSO) Given a $13.00 Price Target by HC Wainwright Analysts (americanbankingnews.com)
- Cytosorbents (CTSO) PT Raised to $12.00 at Maxim Group (americanbankingnews.com)
- Analysts See $1.24 EPS for Unum Group (UNM); Cytosorbents Has 2.89 Sentiment (mtastar.com)
- Healthcare Stock in the Spotlight: Cytosorbents Corporation (CTSO) (stocksgeeks.com)
A number of equities research analysts have recently issued reports on the stock. ValuEngine raised shares of Cytosorbents from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. B. Riley set a $11.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research report on Friday, December 22nd. Cowen set a $9.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research report on Thursday, March 8th. Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research report on Thursday, December 21st. Finally, HC Wainwright set a $14.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research report on Friday, March 9th. Six research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $11.05.
Shares of CTSO traded up $0.10 during trading hours on Friday, reaching $7.80. 100,677 shares of the stock traded hands, compared to its average volume of 179,739. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.54 and a current ratio of 2.64. Cytosorbents has a 52-week low of $3.30 and a 52-week high of $8.25. The stock has a market cap of $222.51, a price-to-earnings ratio of -24.44 and a beta of -0.09.
Cytosorbents (NASDAQ:CTSO) last released its earnings results on Thursday, March 8th. The medical research company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Cytosorbents had a negative net margin of 52.08% and a negative return on equity of 118.07%. The firm had revenue of $4.65 million for the quarter, compared to analysts’ expectations of $4.56 million. equities research analysts predict that Cytosorbents will post -0.47 earnings per share for the current year.
In related news, CFO Kathleen P. Bloch sold 11,176 shares of Cytosorbents stock in a transaction on Thursday, March 15th. The shares were sold at an average price of $8.25, for a total transaction of $92,202.00. Following the transaction, the chief financial officer now owns 261,246 shares in the company, valued at approximately $2,155,279.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Kathleen P. Bloch sold 10,000 shares of Cytosorbents stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. Following the transaction, the chief financial officer now owns 268,870 shares in the company, valued at approximately $2,150,960. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,280 shares of company stock worth $181,310. 5.60% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://transcriptdaily.com/2018/04/13/cytosorbents-ctso-given-coverage-optimism-rating-of-0-23.html.
CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent, porous polymer technology. Its principal product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.